PTPRG and glioblastoma: As NAZ2329 preferentially inhibits both PTPRG and PTPRZ1 (see Fig. 4F), NAZ2329 is expected to be superior to sole inhibitors of PTPRZ or PTPRG for inhibiting the malignant properties of glioblastoma cells.